Q32 Bio Inc（QTTB）股票分析

$13.590

-0.728 (-5.36%)收盤時

Loading chart…

High: 14.550
Open: 14.420
VWAP: 13.83
Vol: 434.82K
Mkt Cap: —
Low: 13.350
Amount: 6.01M
EV/EBITDA, TTM: 0.00

Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.

估值指標

The current forward P/E ratio for Q32 Bio Inc (QTTB) is -0.41, compared to its 5-year average forward P/E of -4.27.

Forward P/E

Overvalued

5Y Average P/E

-4.27

Current P/E

-0.41

高估

-0.91

低估

-7.64

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

高估

0.00

低估

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

高估

0.00

低估

0.00

Whales holding QTTB

A

Arch Venture Partners, L.P.

+ HoldingQTTB

+22.44%

3M Return

事件時間軸

2026-07-17 (ET)

16:30:00

Q32 Bio Files to Sell 6.88M Shares of Common Stock

2026-07-14 (ET)

23:30:00

Morgan Stanley and Others Jointly Manage New Stock Offering

2026-07-13 (ET)

16:30:00

Q32 Bio Commences $200M Public Offering

12:30:00

Major Averages Decline Amid Rising Geopolitical Tensions

07:30:00

Q32 Bio Announces Bempikibart Clinical Trial Results

Show More Events

資訊

QTTB FAQ — answered by Alphio AI

Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。